Table 2.
Clinicopathologic correlation of ERβ.
| Sl no. | Attribute | ERβ positive (n = 58) | ERβ negative (n = 206) | p valuea overall | p valuea PTC | p valuea FTC | p valuea PDTC |
|---|---|---|---|---|---|---|---|
| 1. | Age in years (mean ± SD) | 45.9 ± 14.2 | 46.2 ± 15.9 | 0.865 | 0.371 | 0.707 | 0.086 |
| 2. | Gender (M : F) | 19 : 39 | 71 : 135 | 0.876 | 0.305 | 0.507 | 0.014∗ |
| 3. | Presence of PDAb, n (%) | 11 (24.4) | 79 (43.2) | 0.026∗∗ | 1.000 | 0.212 | — |
| 4. | Tumor size in cm (mean ± SD) | 4.9 ± 3.1 | 4.6 ± 2.7 | 0.540 | 0.807 | 0.279 | 0.068 |
| 5. | Multicentricity, n (%) | 15 (26.3) | 55 (27.4) | 1.000 | 0.679 | 0.668 | 0.389 |
| 6. | Extrathyroidal extension, n (%) | 18 (31.0) | 47 (23.3) | 0.233 | 1.000 | 1.000 | 1.000 |
| 7. | Lymph node metastases, n (%) | 31 (53.4) | 71 (34.6) | 0.014∗∗∗ | 0.836 | 0.117 | 0.310 |
| 8. | Metastases, n (%) | 18 (31.0) | 65 (31.9) | 1.000 | 0.513 | 0.369 | 0.299 |
| 9. | Recurrence, n (%) | 7 (12.0) | 18 (8.7) | 0.445 | 0.550 | 0.158 | 0.305 |
| 10. | Mean survival in months (n ± SE) | 127 ± 8.5 | 197 ± 6.9 | 0.400 | 0.956 | 0.069 | 0.638 |
aAll p values obtained on univariate analysis. b PDA, poorly differentiated areas. ∗Significant positive correlation of ERβ expression and occurrence of PDTC in females. ∗∗Significant negative correlation of ERβ expression and occurrence of PDA. ∗∗∗Significant positive correlation of ERβ expression and incidence of lymph nodal metastases.